BioMarin slides as Roctavian exit spotlights dependence on Voxzogo growth
BioMarin shares fell after it pulled hemophilia gene therapy Roctavian off the market and took a $119 million inventory write-off tied to the product. The decline also reflects renewed focus on BioMarin’s reliance on Voxzogo as its biggest revenue driver and near-term growth engine.
1. What’s moving the stock
BioMarin Pharmaceuticals (BMRN) is trading lower as investors digest the company’s decision to remove Roctavian, its hemophilia A gene therapy, from the market and the financial hit tied to that exit. The Roctavian decision has refocused attention on portfolio concentration and the durability of BioMarin’s remaining growth drivers, particularly Voxzogo.
2. Why it matters now
Roctavian was positioned as a high-profile gene-therapy launch, and stepping away effectively closes the door on a potential long-duration growth lever for the company. The move increases the market’s sensitivity to any changes in Voxzogo demand, pricing, reimbursement, or safety perceptions, because Voxzogo has become BioMarin’s largest revenue contributor.
3. Key figures and context investors are weighing
BioMarin’s Roctavian-related charges included a $119 million inventory write-off, underscoring the cost of discontinuing commercial efforts around the product. Separately, BioMarin has guided to 2026 revenue of about $3.3 billion to $3.4 billion (excluding any post-close contribution from the pending Amicus transaction), keeping the spotlight on core execution while the company works toward closing the Amicus acquisition in Q2 2026.
4. What to watch next
Near-term trading may hinge on whether additional details emerge on Roctavian wind-down costs, any implications for BioMarin’s manufacturing footprint, and updated commentary on Voxzogo momentum. Investors will also watch for incremental regulatory and closing-condition updates on the Amicus deal, given BioMarin’s financing steps to support the acquisition and the market’s sensitivity to timelines.